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Case Report
Factor VII deficiency and pregnancy: A case report and review of literature
Syed Mohammad Asad Zaidi,1 Rahat Najam Qureshi,2 Salman Naseem Adil3

Medical Student,1 Department of Obstetrics and Gynecology,2 Department of Hematology-Oncology,3
Aga Khan University, Medical College, Karachi, Pakistan.

Abstract

Factor VII deficiency is one of the 'rare inherited
disorders of coagulation.' Few cases of Factor VII deficiency
have been reported during pregnancy, a state which could
potentially cause fatal haemorrhage. Here we report a case of
a pregnant lady with a history of heavy menorrhagia and
multiple first pregnancy failures. Delivery was carried out via
Caesarean section due to non-reassuring foetal heart
monitoring. Patient was treated with Fresh Frozen Plasma
(FFPs) and Factor VII concentrates, however, the patient
developed bleeding postoperatively. Literature indicates that
whilst Factor VII levels rise during pregnancy in normal
women, no increase is seen in homozygous cases, whereas
there is a moderate rise in heterozygous individuals. History of
heavy menorrhagia, multiple first pregnancy failures and a
positive family history for bleeding disorders necessitate
investigation and monitoring of Factor VII levels during
pregnancy. Factor VII concentrates achieve adequate
homeostasis in most cases. Recombinant Factor VIIa,
however, is the treatment of choice and does not carry a risk
of infection transmission or thrombus formation.

many heterozygous carriers may begin to bleed even at higher
Factor VII levels. These factors make it difficult to identify
patients at risk for ante-partum complications and in deciding
treatment modalities. The choice of treatment depends on its
efficacy, costs, clinical assessment of the patient, risk of
infection transmission and developing thrombosis.
Here we report a case of Factor VII deficiency during
pregnancy and a review of management of such cases.

Case Report

A 28-year-old Gravide III, Para 0+2 woman at the
39th week of pregnancy, known case of Factor VII
deficiency and pregnancy induced hypertension presented
to the Emergency Room.

Inherited deficiencies of Factor VII are among the 'rare
inherited disorders of coagulation.' This bleeding disorder has
an estimated prevalence of 1 per 500 000 in its severest form,
to one in 350 in the heterozygous state.1

This patient had first presented to this hospital at the
age of fifteen with a history of heavy menorrhagia since the
onset of menarche (eight months previously). In addition, she
had complaints of weight loss, weakness, fatigue and
examination revealed extreme pallor. Laboratory reports
revealed severe microsytic, hypochromic anaemia (Hb 2.7,
HCt 9.2%, RBC 1.78). She was subsequently managed on
blood transfusions, platelets, fresh frozen plasma (FFPs),
norethisterone, transexamic acid, NSAIDs and iron
supplements. On follow up visits to the clinic, over the next
ten years, she was treated under a diagnosis of Dysfunctional
Uterine Bleeding followed by Dilatation and Curettage for
acute exacerbation of symptoms.

The serious clinical manifestation of Factor VII
deficiency during labour is haemorrhage. This can occur from
the site of the placenta, genital lacerations, episiotomies or
during Caesarean sections.1
The generally held view is that for patients with Factor
VII deficiency, bleeding diathesis does not become clinically
manifest unless the level is <10 IU/dL. This commonly occurs
in the severe form of the disease which causes spontaneous
bleeding. The range for heterozygous carriers is 20-60 IU/dL,
hence, a majority of these cases are incidental discoveries.4
However, a poor correlation has been shown between the
levels of Factor VII and the risks of bleeding.5 As a result,

The third pregnancy was uneventful until the 27th
week when she was admitted for two episodes of haematuria.
She was managed with 4 units of FFPs and was later
discharged when there was no further evidence of bleeding.
At this admission, the patient presented to the
Emergency Room with labour pains. On examination she was
not in active labour and foetal heart monitoring revealed a
non-reassuring trace, therefore, an emergency caesarean
section was planned. Pre-operatively she was infused a single

Introduction

Few cases have been reported of Factor VII deficiency
during pregnancy. Pregnancy has shown to elevate Factor VII
levels in normal women whereas no significant increase
occurs in homozygous deficiencies.2,3
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During the previous year, she had two missed
abortions that required Dilatation and Evacuation. During her
second pregnancy, suspicion of a hereditary bleeding disorder
was raised after her sister was diagnosed with Factor VII
deficiency. Upon visiting the haematology clinic, coagulation
profile showed PT 62, INR 5.28, APTT 21, Factor VII levels
at 2.4 % and a diagnosis with Factor VII deficiency was made.
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dose of Factor VII concentrate and 3 units of FFPs 8 hourly,
prophylacticaly. Caesarean Section was performed later that
night during which she was given an additional 6 units of FFP
and 4 units of cryoprecipitate. A healthy baby boy was
delivered weighing 2.9 Kg with an APGAR score of 9 at five
minutes. The estimated blood loss during the procedure was
800ml. Red rubber and Redivac drainage tubes were placed
intra-operatively and collected 90cc and 10 cc of blood,
respectively, 6 hours post-operatively. Post-operative
coagulation profile revealed PT 9.4, INR 0.9, APTT 32.3
while her Hb had dropped from 14.9 to 13.2. She was
continued on 3units of FFPs 8 hourly, Transexamic acid
500mg intravenously and antibiotics. She was given TED
stockings and regular physiotherapy sessions and closely
monitored for any signs of DVT (Deep Venous Thrombosis).
Vitally the patient remained stable during the post-operative
period and did not develop fever.
On the 3rd post-op day, the Redivac drain showed an
increase of 15cc with a concomitant drop of haemoglobin to
10.6, hence, FFP infusion was increased to every 6 hours. By
the 5th post-op day, there was no evidence of further bleed,
sutures and drains were removed and FFPs were tapered to 3
units BID. The patient was eventually discharged on the 8th
post-operative day on oral transexamic acid 250 mg 6 hourly
for four days and oral antibiotics.

Discussion

The management of Factor VII deficiency during
pregnancy involves a balancing act of achieving adequate
haemostasis to control excessive ante-partum haemorrhage
and to prevent a state of hypercoagubility that will lead to
thrombus formation. The normal physiological rise of Factor
VII during pregnancy is impaired in cases with homozygous
deficiencies, however, a recent case-series revealed that
women with mild-moderate disease show an increase in
Factor VII levels from a mean baseline of 33 IU/dL to 73
IU/dL at term.3 Majority of women in the case series that
were not given any prophylactic treatment and delivered at
full term without significant postpartum haemorrhage.
Patients with mild-moderate disease on the other hand may
be managed expectantly. This study, however, is limited by
sample size and results have not been hitherto replicated.
Furthermore, early pregnancy losses are likely to occur as any
expected rise occurs late during the third trimester. Cases
with severe disease, therefore, require prophylactic therapy as
part of management.

FFPs may be utilized for management due to easy
availability and less thrombogenic potential over
prothrombin complexes and other concentrates.6 However,
fatal thrombosis has been described in cases with congenital
Factor VII deficiencies, hence, evidence of hypercoagubility
needs to be closely monitored.7 Factor VII concentrates
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instead are more effective in preventing ante-partum
haemorrhage and carry a low risk of viral infection
transmission and pulmonary oedema.8
More recently, recombinant Factor VIIa (rFVIIa) has
become the treatment of choice. The advantage of using
recombinant Factor VIIa results from its specific action at the
site of vessel injury leading to a low thrombogenic risk. This
has been demonstrated using thromboelastographic
monitoring to study efficacy of rFVIIa in Factor VII
deficiency during pregnancy which effectively reduces risk
of bleeding without placing coagulation in prothrombotic
range.9 There are no clear guidelines for the use of rFVIIa in
obstetric cases with deficiencies of Factor VII. Due to its
short half-life (approx 2.7h), appropriate dosage was a
problem in the few reported cases that utilized rFVIIa.
Continuous infusion of rFVIIa has been recommended
instead of a single dose in a case report of a Factor VII
deficient patient that underwent a caesarean delivery.10

Conclusion

Our patient was most likely a case of heterozygous
Factor VII deficiency. She had a family history of bleeding
disorders and a past history of heavy menorrhagia and first
trimester pregnancy failures. These features were also the
most consistent findings in the reported literature, hence,
warrant investigations for an inherited bleeding disorder if
present within a patient's history. A combination of
prophylactic Factor VII concentrates as well as FFPs had to
be utilized to control post-operative haemorrhage for our
patient. This demonstrates the ineffectiveness of Factor VII
concentrates when compared to recombinant Factor VIIa,
however, the former remains the treatment of choice in
developing countries where cost and availability of products
need to be considered. Alternatively, evidence suggests that
heterozygous cases may be managed expectantly.
Continuous infusion of recombinant Factor VIIa is the
treatment of choice in homozygous cases.
1.
2.
3.
4.
5.
6.
7.
8.
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